Last reviewed · How we verify

Short bowel syndrome — Treatment Landscape & Competitive Intelligence

Short bowel syndrome (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Short bowel syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Gattex Kit TEDUGLUTIDE Takeda GLP-2 Analog [EPC] Glucagon-like peptide 2 receptor 2012-01-01
Nutrestore GLUTAMINE Emmaus Medcl Amino Acid [EPC] 2004-01-01
Glutamin Glutamin Shahid Beheshti University Amino acid transporter

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Emmaus Medcl · 1 drug in Short bowel syndrome
  2. Shahid Beheshti University · 1 drug in Short bowel syndrome
  3. Takeda · 1 drug in Short bowel syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Short bowel syndrome:

Cite this brief

Drug Landscape (2026). Short bowel syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/short-bowel-syndrome. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing